Australia's Orthocell rises after tariff relief on key product

Orthocell

08/04/2026 06:59

** Shares of Australia's Orthocell OCC.AX rise as much as 7.9% to A$0.82, their biggest intraday pct gain since March 31

** Regenerative medicine
says
 flagship product Remplir not expected to be subject to proposed U.S. pharmaceutical tariffs

** President Donald Trump signed an executive order on April 2, imposing
100% tariffs
 on branded pharmaceuticals imported into the U.S. unless manufacturers agree to government drug pricing deals or commit to making their products domestically

** Despite moves, stock down 25.4% YTD

 (Reporting by Aamir Sheik Khalid in Bengaluru)

 ((Aamir.SheikKhalid@thomsonreuters.com))